E-LIB Suche - Ergebnisse für: Lii-Rosales, Ann

1

Efficacy and Safety of Atezolizumab plus Bevacizumab versus..:

Finn, Richard S. ; Galle, Peter R. ; Ducreux, Michel...
Liver Cancer. , 2024

Link: https://doi.org/10.1159/..

2

Outcomes of Post-Immunotherapy Durable Responders of Advanc..:

Liu, Tsung-Hao ; Chen, San-Chi ; Rau, Kun-Ming...
Liver Cancer. , 2024

Link: https://doi.org/10.1159/..

3

Cyclin dependent kinase 9 inhibition reduced programmed dea..:

Shao, Yu-Yun ; Hsieh, Min-Shu ; Lee, Yi-Hsuan...
Heliyon. 10 (2024) 14 - p. e34289 , 2024

Link: https://doi.org/10.1016/..

4

Interaction of base excision repair gene polymorphism and e..:

Chen, Hsing-Wu ; Kuo, Wen-Hung ; Lu, Yen-Shen...
Breast Cancer Research and Treatment. , 2024

Link: https://doi.org/10.1007/..

5

Changes in Posttreatment Spleen Volume Associated with Immu..:

Chen, Bang-Bin ; Liang, Po-Chin ; Shih, Tiffany Ting-Fang...
Journal of Hepatocellular Carcinoma. 11 (2024) - p. 1015-1029 , 2024

Link: https://doi.org/10.2147/..

6

Tu1578 IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS ..:

Finn, Richard S. ; Breder, Valeriy ; Vogel, Arndt...
Gastroenterology. 166 (2024) 5 - p. S-1738 , 2024

Link: https://doi.org/10.1016/..

7

Impact of Bevacizumab Being Skipped due to Adverse Events o..:

Kudo, Masatoshi ; Tsuchiya, Kaoru ; Shao, Yu-Yun...
Liver Cancer. , 2023

Link: https://doi.org/10.1159/..

8

Plain language summary of the HIMALAYA study: tremelimumab ..:

Abou-Alfa, Ghassan K ; Lau, George ; Kudo, Masatoshi...
Future Oncology. 19 (2023) 38 - p. 2505-2516 , 2023

Link: https://doi.org/10.2217/..

9

Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevac..:

Kudo, Masatoshi ; Finn, Richard S. ; Cheng, Ann-Lii...
Liver Cancer. 12 (2023) 5 - p. 479-493 , 2023

Link: https://doi.org/10.1159/..

10

Lenvatinib plus pembrolizumab versus lenvatinib plus placeb..:

Llovet, Josep M ; Kudo, Masatoshi ; Merle, Philippe...
The Lancet Oncology. 24 (2023) 12 - p. 1399-1410 , 2023

Link: https://doi.org/10.1016/..

11

Overall survival and objective response in advanced unresec..:

Kudo, Masatoshi ; Finn, Richard S. ; Qin, Shukui...
Journal of Hepatology. 78 (2023) 1 - p. 133-141 , 2023

Link: https://doi.org/10.1016/..

12

Atezolizumab plus bevacizumab versus active surveillance in..:

Qin, Shukui ; Chen, Minshan ; Cheng, Ann-Lii...
The Lancet. 402 (2023) 10415 - p. 1835-1847 , 2023

Link: https://doi.org/10.1016/..

13

Topoisomerase I Inhibition Radiosensitizing Hepatocellular ..:

Tsai, Chiao-Ling ; Yang, Po-Sheng ; Hsu, Feng-Ming...
Journal of Clinical and Translational Hepatology. 000 (2023) 000 - p. 000-000 , 2023

Link: https://doi.org/10.14218..

14

Pembrolizumab as Second-Line Therapy for Advanced Hepatocel..:

Merle, Philippe ; Kudo, Masatoshi ; Edeline, Julien...
Liver Cancer. 12 (2023) 4 - p. 309-320 , 2023

Link: https://doi.org/10.1159/..

15

Overall survival with cetuximab every-2-weeks versus standa..:

Kasper, Stefan ; Foch, Caroline ; Esser, Regina...
European Journal of Cancer. 180 (2023) - p. 85-88 , 2023

Link: https://doi.org/10.1016/..